Clinical Trial Update: A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma [Phase 4]

View source ↗

Summary

This clinical trial update describes a Phase 4 study of liposomal irinotecan for advanced neuroendocrine carcinoma that is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• Onivyde (liposomal irinotecan) (liposomal irinotecan)

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: Neuroendocrine Carcinomas (NEC) | Phase 4 | Status: NOT_YET_RECRUITING